Craniopharyngioma With Tumoral Hemorrhage

NCT04937335 | Completed

• 1 other identifier: kaishu1
• Study Type: observational
• Target: 185
• Locations: 0 countries
• Sites: N/A

Brief Summary

Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected. Among these patients, 18 of them were recognized as craniopharyngioma with tumoral hemorrhage during the operation.

Conditions

Craniopharyngioma; Apoplexy

Keywords

craniopharyngioma; endocrine; risk factor; tumoral hemorrhage

Outcome Measures

Primary Outcomes (1)

• craniopharyngioma with tumoral hemorrhage

  Current study is a case-control study whose primary outcome is tumoral hemorrhage observed during the operation, which devided the craniopharyngioma patients into hemorrhage group and non-hemorrhage group.

  during the operation

Study Arms (2)

Non-hemorrhage group

Patients recognized as craniopharyngioma pathologically without tumoral hemorrhage observed during the operation

Hemorrhage group

Patients recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation

Other: intratumoral hemorrhage

Interventions

intratumoral hemorrhage OTHER

Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.

Hemorrhage group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with a pathological diagnosis of craniopharyngioma

You may qualify if:

• receive resective operation with a pathological diagnosis of craniopharyngioma in our hospital
• enter our hospital between January 2013 and February 2021

You may not qualify if:

• have a non-craniopharyngioma or unverified pathological diagnosis at discharge
• have received surgical or radiological treatment on the sellar region
• receive treatment of coagulation modulation, immunosuppressive agents or chemotherapeutic drugs
• combine with other clinical emergencies including acute myocardial infarction, cerebral stroke, trauma and sepsis at admission
• have been diagnosed with other tumors, hematological diseases, autoimmune diseases, liver failure or renal failure

Sponsors & Collaborators

• Tongji Hospital: lead

MeSH Terms

Conditions

Craniopharyngioma; Stroke

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Kai Shu, MD

  Tongji Hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr.

Study Record Dates

• First Submitted: June 7, 2021
• First Posted: June 24, 2021
• Study Start: January 1, 2013
• Primary Completion: February 1, 2021
• Study Completion: February 1, 2021
• Last Updated: June 24, 2021

Record last verified: 2021-06

Data Sharing

• IPD Sharing: Will not share